
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc. is demonstrating a positive outlook due to significant advancements in its clinical programs, particularly the promising results of icovamenib's Phase II trial and the initiation of BMF-650's Phase I trial, indicating strong potential for diabetes and obesity treatment. Financially, the company has shown improvement with a reduced net loss of $16.4 million in Q3 2025 compared to $32.8 million in Q3 2024, alongside a more than 50% decline in operating expenses year-over-year. Moreover, the favorable pharmacokinetic profile and safety findings further bolster investor confidence in the company's pipeline as it prepares for upcoming trials.
Bears say
Biomea Fusion Inc. has reported a significant decrease in research and development (R&D) expenses, dropping from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, which may raise concerns regarding the company's investment in its drug pipeline. General and administrative (G&A) expenses also saw a decline from $6.8 million to $4.2 million, suggesting potential cost-cutting measures that could impact operational capabilities. Furthermore, the reduction in the price target from $16.00 to $12.00 indicates a reevaluation of the company's growth prospects and overall market confidence.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares